Date:November 02, 2012

Terzah Horton, M.D., Ph.D.

Terzah Horton, M.D., Ph.D.Assistant Professor
Department of Pediatrics
Section of Hematology-Oncology
Baylor College of Medicine

Hyundai Pediatric Cancer Research Scholar

Dr. Terzah Horton
Texas Children’s Cancer Center
1102 Bates Street, Suite 750.01
Houston, TX 77030

Phone: 832-824-4269
Fax: 832-825-1206
Email: tmhorton@txch.org

About Dr. Terzah Horton

Dr. Terzah Horton is a graduate of Emory University where she received her M.D. from the Emory University School of Medicine, as well as her Ph.D. She also attended her fellowship in pediatric hematology/oncology at Emory University and Baylor College of Medicine where she later became a faculty member in the Developmental Therapeutics Program at Texas Children’s Hospital, the pediatric teaching hospital of Baylor College of Medicine. Dr. Horton is a board-certified member of the American Board of Pediatrics and is a board-certified specialist in pediatric Hematology Oncology.

Dr. Horton’s clinical interests in oncology include developmental therapeutics.

Dr. Terzah Horton is a member of the Developmental Therapeutics Program, the Leukemia Program, and the Lymphoma Program at Texas Children’s Cancer Center.


M.D. and Ph.D., Emory University School of Medicine
Fellowship, Emory University
Residency and Fellowship, Baylor College of Medicine
Clinical Pharmacology Program, Baylor College of Medicine

Board Certifications

American Board of Pediatrics
American Board of Pediatrics-Hematology/Oncology
Clinical Scientist Training Program

Selected Memberships

Member, American Academy of Pediatrics (AAP)
Member, American Society for Pediatric Hematology-Oncology (ASPHO)
Member, American Association of Cancer Research (AACR)
Member, Children’s Oncology Group (COG)
Member, American Society for Clinical Oncology (ASCO)
American Society for Clinical Pharmacology and Therapeutics (ASCPT)

Clinical Interests

New Drug Development

Research Interests

Molecular causes of leukemia and lymphoma
Proteomics and the deregulation of cell cycle protein degradation during the development of malignancy
Developmental Therapeutics

The Research Laboratory of Dr. Terzah Horton

Dr. Terzah Horton’s research focuses on the molecular changes in cell cycle genes/proteins that might cause leukemias and lymphomas. Her goal is to identify molecular defects contributing to leukemia and lymphoma. By doing this, more knowledge may be gained regarding the predisposition to cancer development in leukemias, and in turn, light may be shed on the process of cancer development and growth regulation in general.

Dr. Terzah Horton is also interested in proteomics and the deregulation of cell cycle protein degradation during the development of malignancy, particularly leukemias and lymphomas. She is particularly interested in ubiquitination and the alterations that occur in the ubiquitin pathway during carcinogenesis. She is currently the study coordinator for two Phase II clinical trials as a member of the Developmental Therapeutics Program.

Laboratory Members

Principal Investigator
Terzah Horton, M.D., Ph.D.

Research Assistants

Will Weathers

Will Weathers

Gaye Jenkins

Gaye Jenkins


Methods (PDFs)

Protein lysates for Western blots

Isolation of PBMC from bone marrow/blood and apoptosis flow cytometry for ADVL0317

Isolation of PBMC for bone marrow/blood for ADVL0411

MTT assay Protocol

Western blots using BioRad setup

NF-kB nuclear lysates and ELISA


Open Clinical Trials: NIH guide


A Jayanthan, S Howard, T Trippet, TM Horton, L Daisley, & A Narendran. Targeting the Bcl-2 family of proteins in Hodgkin Lymphoma: In vitro cytotoxicity, target modulation and drug combination studies of the BH3 mimetic ABT-737. Leukemia and Lymphoma, 2009. 50:1174-82. PMID: 19557638

JA Muscal, PA Thompson, VL Geranda, BD Dayton, J Bauch, TM Horton, L McGuffey, JG Nuchtern, RC Dauser, BW Gibson, SM Blaney and JM Su.  Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. Cancer Chemother. Pharmacol. 2009. In press. PMID: 19526240

TM Horton, G Jenkins, D Pati, L Zhang, MD Dolan, A Ribes-Zamora, AA Bertuch, SM Blaney, SL Delaney, M Hegde and SL Berg. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther. 2009. 8:2232-42. PMID: 19671751

TM Horton, R Sposto, P Brown, CP Reynolds, SP Hunger, NJ Winick, AE Raetz, WL Carroll, RJ Arceci, MJ Borowitz, PS Gaynon, L Gore, S Jeha, BJ Maurer, WE Siegel, A Biondi, PR Kearns, A Narendran, LB Silverman, MA Smith, CM Zwaan JA Whitlock. Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): Review from an international consensus conference. Pediatric Blood and Cancer. 2009. In press.

TM Horton, D Pati, SE Plon, PA Thompson, LR Bomgaars, PC Adamson, AM Ingle, J Wright, AH Brockman, M Paton, SM Blaney. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia; A Children’s Oncology Group study. Clin. Cancer Res. 2007. 13: 1516-22.

TM Horton, PA Thompson, SL Berg, PC Adamson, AM Ingle, E Dolan, M Hedgi, and SM Blaney. A Phase 1 Trial of Temozolomide in Pediatric Patients with Refractory/Recurrent Leukemias: A Children’s Oncology Group Study.  J. Clin. Oncol. 2007. 25:4922-8.

TM Horton, SE Plon, A Gannavarapu, SM Blaney, D D’Argenio, SL Berg.  Bortezomib potentiation of chemotherapy agents in acute leukemia in vitro. Cancer Chemotherapy and Pharmacology. 2006. 58: 13-23.

TM Horton, MM Ames, JM Reid, MD Krailo, T Pendergrass, SP Ivy, R Mosher, GH Reaman, N Seibel. Paclitaxel for Treatment of Refractory Leukemia in Children: A Phase 1 Study of the Children’s Oncology Group.  Pedi. Blood and Cancer. 2007,50(4):788-92.
DJ Min, NP Moskowitz, C Brownstein, H Lee, TM Horton, and WL Carroll. Diverse Pathways Mediate Chemotherapy-Induced Cell Death in Acute
Lymphoblastic Leukemia Cell Lines. Apoptosis. 2006. 11:1977-86.

TM Horton, SE Plon, A Gannavarapu, SM Blaney, D D’Argenio, SL Berg. Bortezomib potentiation of chemotherapy agents in acute leukemia in vitro. Cancer Chemotherapy and Pharmacology.

TM Horton, SM Blaney, A-M langevini, J Kuhn, B kamen, SL Berg, M Berstein, S Weitman. Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: A pediatric oncology group study. Clin. Cancer Res.2005. 11:1884-1889.

MN Suell, TM Horton, MK Dishop, DH Mahoney, OO Olutoye, BU Mueller. Outcomes for children with gallbladder abnormalities and sickle cell disease. J. Pediatrics. 2004. 145:617-621.

SM Blaney, M Bernstein, K Neville, J Ginsberg, B. Kitchen, TM Horton, SL Berg, M Krailo, PC Adamson. A Phase 1 study of the proteasome inhibitor PS-341 in pediatric patients with refractory solid tumors: A Children’s Oncology Group study. J Clin Oncol.2004. 22:4752-4757.

TM Horton, JD Stone, D Yee, Z Dreyer, JL Moake, DH Mahoney. A case series of thrombotic thrombocytopenic purpura (TTP) in children and adolescents. J. Ped. Hematol.Oncol. 2003. 25:336-339.

Pease, CL, TM Horton, K McClain, S Kaplan. Aseptic meningitis in a child following systemic treatment with high-dose cytarabine. Ped. Infect. Dis. J. 2001 20:87-89.

Horton TM, JA Petros, A Heddi, JM Shoffner, K Houponon, SD Graham, T Gramlich, and DC Wallace. A novel mitochondrial DNA deletion found in a renal cell carcinoma. Genes, Chromosomes and Cancer. 1996. 5:1-7.